Special Summer 2025Lab automation: New ModalitiesMore visitors, more exhibitors and more new product launches at SLAS Europe in Hamburg. more ➔
Special Summer 2025Euro BioFairs CompassGuide to Life Sciences Events in the second half year of 2025 more ➔
Special Summer 2025(Bio)EngineeringRegions and industry leaders are already preparing for the future. This Special spotlights emerging open innovation clusters and cutting-edge bioengineering platforms. more ➔
Special Spring 2025Oligonucleotides and PeptidesPeptide drugs recorded global sales in Europe. The market for gene and cell therapy contract manufacturing, oligonucleotide synthesis and the production of viral vectors and plasmids is also expanding … more ➔
Special Winter 2025Preview: Drug Delivery ServicesAlthough smart drug delivery accounts for only 10% of drug development costs, significant efforts have been made to optimise drug properties such as solubility, stability and release kinetics, while … more ➔
Special Winter 2025Preview: Talent scouting & educationFaced with a severe shortage of skilled labour, specialised biopharma companies and service providers such as CROs and CDMOs are competing globally for the best minds. Active recruitment and retention … more ➔
Special Winter 2025Preview: Automation in quality controlBy modelling the (bio)manufacturing processes digitally, companies can simulate different conditions, optimise parameters, and improve efficiency without disrupting actual production. Using a simulation … more ➔
Special Autumn 2025Preview: CROs & CDMOsCDMOs and CROs are under great pressure to integrate new trial designs and drug formats – including ATMPs, ADCs, condensate blockers, RNA drugs and formulations as well as automated preclinical testing … more ➔
Special Autumn 2025Preview: Automation & data scienceEuropean Biotechnology Magazine’s comprehensive special feature ‘Lab automation & data sciences/AI’, created in cooperation with the Society for Laboratory Automation and Screening (SLAS), provides … more ➔
Special Autumn 2025Preview: ADCs & beyondAntibody-drug conjugates and targeted radiopharmaceuticals promised chemotherapies and radiotherapies with fewer side effects by delivering cytotoxic cargos more specifically to the site of action, usually … more ➔
